HSP90AA1 and neoplasm: The co-treatment of 17-MAG and antibody against HSP90 client protein EphA2 effectively reduces immune suppressor cell populations, such as myeloid-derived suppressor cell and regulatory T cells, while recruiting Type-1 T effector cells through chemokines such as CXCL10 and enhancing the recognition of tumor cells by CD8+ T cells [142].